LYMEPAK Drug Patent Profile
Which patents cover Lymepak, and when can generic versions of Lymepak launch?
Lymepak is a drug marketed by Chartwell Pharma and is included in one NDA.
The generic ingredient in LYMEPAK is doxycycline hyclate. There is one drug master file entry for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lymepak
A generic version of LYMEPAK was approved as doxycycline hyclate by STRIDES PHARMA on March 29th, 1982.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LYMEPAK?
- What are the global sales for LYMEPAK?
- What is Average Wholesale Price for LYMEPAK?
Summary for LYMEPAK
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 52 |
| Patent Applications: | 2,651 |
| What excipients (inactive ingredients) are in LYMEPAK? | LYMEPAK excipients list |
| DailyMed Link: | LYMEPAK at DailyMed |
US Patents and Regulatory Information for LYMEPAK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell Pharma | LYMEPAK | doxycycline hyclate | TABLET;ORAL | 209844-001 | Jun 15, 2018 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
